Skip to content
Our reporters bring you news and highlights from BIO’s in-person and virtual events.
The BIO Delegation (pictured from left): Tasuku Kitada (Strand Therapeutics), Adam Roach (BeOne Medicines, formerly Beigene), Jacob Becraft (Strand Therapeutics), John F. Crowley (BIO), […]
BIO’s mission to Tokyo builds on fruitful cooperation Read More »
When it comes to biotech M&A, 2024 wasn’t a great year, but it wasn’t “horrible,” according to analysts at the BIO CEO & Investor
M&A comeback may face political headwinds, say BIO CEO panelists Read More »
The U.S. Food and Drug Administration’s Accelerated Approval Pathway enables the timely development of treatments for severely ill patients who have few if any
BIO coffee chat focuses on reimbursement for Accelerated Approval Pathway drugs Read More »
Seeking biotech-friendly policy from the new administration and Congress will be daunting and perhaps confusing, but there are still a lot of potential wins
BIO CEO 2025: Challenges and opportunities in the new administration Read More »
Despite a pressing demand, schizophrenia has had limited treatment. “Roughly 1% of the entire world population has schizophrenia,” said Boobalan Pachaiyappan, Managing Director and
BIO CEO 2025: New solution for the challenge of schizophrenia Read More »
The idea of AI supercharging drug development is stirring a lot of excitement. However, a realistic understanding of what AI can and can’t do
BIO CEO 2025: AI is a tool – not magic Read More »
While a couple of frontrunners have taken the early lead in the race to capture the market for obesity drugs, major pharmaceutical firms still
BIO CEO 2025: Exciting new directions for obesity drug research Read More »
The year in biotech M&A activity got off to a promising start at JPM Week with announcements of some multi-billion-dollar deals. The flurry of
Multi-billion-dollar deals at JPM Week augur a busy BIO CEO 2025 Read More »
Pharmacy benefit managers (PBMs) create unnecessary barriers between patients and the medicine they need, experts explained during a Nov. 25 virtual “Patient Advocacy Coffee
Harms of PBMs explained in BIO Patient Advocacy Coffee Chat Read More »
Pictured above, Rep. Deborah Ross (D-NC) addresses the opening session of BIO’s Intellectual Property Counsels Committee Conference in Washington, D.C., on Nov. 18. The
BIO IP conference promotes protection of innovation Read More »
